

**TABLE 445-9 DOSAGE AND ADVERSE EFFECTS OF COMMONLY USED ANTIEPILEPTIC DRUGS**

Generic Name	Trade Name	Principal Uses	Typical Dose; Dose Interval	Half-Life	Therapeutic Range	Adverse Effects		
						Neurologic	Systemic	Drug Interactions <sup>a</sup>
Carbamazepine	Tegretol <sup>c</sup>	Tonic-clonic Focal-onset	600–1800 mg/d (15–35 mg/kg, child); bid (capsules or tablets), tid-qid (oral suspension)	10–17 h (variable due to autoinduction: complete 3–5 wk after initiation)	4–12 µg/mL	Ataxia Dizziness Diplopia Vertigo	Aplastic anemia Leukopenia Gastrointestinal irritation Hepatotoxicity Hyponatremia	Level decreased by enzyme-inducing drugs <sup>b</sup>  Level increased by erythromycin, propoxyphene, isoniazid, cimetidine, fluoxetine
Clobazam	Onfi	Lennox-Gastaut syndrome	10–40 mg/d (5–20 mg/d for patients <30 kg body weight); bid	36–42 h (71–82 h for less active metabolite)	Not established	Fatigue Sedation Ataxia Aggression Insomnia	Constipation Anorexia Skin rash	Level increased by CYP2C19 inhibitors
Clonazepam	Klonopin	Absence Atypical absence Myoclonic	1–12 mg/d; qd-tid	24–48 h	10–70 ng/mL	Ataxia Sedation Lethargy	Anorexia	Level decreased by enzyme-inducing drugs <sup>b</sup>
Ethosuximide	Zarontin	Absence	750–1250 mg/d (20–40 mg/kg); qd-bid	60 h, adult 30 h, child	40–100 µg/mL	Ataxia Lethargy Headache	Gastrointestinal irritation Skin rash Bone marrow suppression	Level decreased by enzyme-inducing drugs <sup>b</sup> Level increased by valproic acid
Ezogabine	Potiga	Focal-onset	800–1200 mg/d; tid	7–11 h	Not established	Dizziness Fatigue Sedation Confusion Vertigo Tremor	Retinal abnormalities Skin discoloration Cardiac conduction (QT interval prolongation) Urinary retention	Level decreased by enzyme-inducing drugs <sup>b</sup>
Felbamate	Felbatol	Focal-onset Lennox-Gastaut syndrome Tonic-clonic	2400–3600 mg/d, tid-qid	16–22 h	30–60 µg/mL	Insomnia Dizziness Sedation Headache	Aplastic anemia Hepatic failure Weight loss Gastrointestinal irritation	Increases phenytoin, valproic acid, active carbamazepine metabolite
Gabapentin	Neurontin	Focal-onset	900–2400 mg/d; tid-qid	5–9 h	2–20 µg/mL	Sedation Dizziness Ataxia Fatigue	Gastrointestinal irritation Weight gain Edema	No known significant interactions
Lacosamide	Vimpat	Focal-onset	200–400 mg/d; bid	13 h	Not established	Dizziness Ataxia Diplopia Vertigo	Gastrointestinal irritation Cardiac conduction (PR interval prolongation)	Level decreased by enzyme-inducing drugs <sup>b</sup>

*(Continued)*